News on Medial

Marwari Catalysts unveils Rs 4,000 Cr Impact Fund

EntrackrEntrackr · 2d ago
Marwari Catalysts unveils Rs 4,000 Cr Impact Fund
Medial

Marwari Catalysts unveils Rs 4,000 Cr Impact Fund Backed by over 150 co-investors, family offices and 200+ global mentors, the initiative coincides with MCats’ expansion into Dubai and Singapore. Marwari Catalysts (MCats), a Jodhpur-based startup accelerator, has announced plans to build a Rs 4,000 crore ($500 million) impact-focused portfolio by 2027. “We believe valuations shouldn’t eclipse values,” said Sushil Sharma, founder of Marwari Catalysts. “This fund is our blueprint for a more resilient and inclusive India. Success isn’t just about unicorns; it’s about building companies that improve lives and create lasting social change.” Since inception, MCats has invested in more than 100 early-stage ventures nationwide, generating over 5,000 jobs. Around 35% of its portfolio companies are led by women co-founders, with several key leadership roles also held by women. Through its investments and mentoring programmes, MCats aims to advance multiple UN Sustainable Development Goals (SDGs), including quality education, gender equality, decent work and economic growth, sustainable cities and climate action. Disclaimer: Bareback Media has recently raised funding from a group of investors. Some of the investors may directly or indirectly be involved in a competing business or might be associated with other companies we might write about. This shall, however, not influence our reporting or coverage in any manner whatsoever.

Related News

IXP unveils Rs 200 Cr early-stage fund for lifesciences startups

EntrackrEntrackr · 6m ago
IXP unveils Rs 200 Cr early-stage fund for lifesciences startups
Medial

IXP, a Life Sciences VC backed by JV Ventures, has announced the launch of its first fund to invest in early-stage companies. The fund aims to build a portfolio of B2B companies ranging from pre-seed to Series A stages. The IXP Lifesciences Catalyst Fund is targeting a corpus of Rs 200 crore, with a greenshoe option of Rs 100 crore. The fund plans to create a portfolio of 20-25 companies addressing gaps in the market for both services and products. Within the Life Sciences sector, the fund will invest in innovations across areas such as pharma, biotechnology, medical technology, specialty chemicals, agrotechnology, and nutraceuticals. Through IXP Venture Studio, it will co-create companies alongside scientists to develop ideas that address unmet market needs. Unlike traditional VCs, it takes a hands-on approach, actively participating from concept to scale. The Venturepreneur Program has been designed to transform scientists into founders. According to IXP, early-stage companies require access to larger ecosystems, including laboratories, networks, and R&D services, which it provides through PoweRx, the Life Sciences vertical of JV Ventures. The VC firm leverages synergies within the group to create a winning proposition for portfolio companies. IXP (Innovation Acceleration Platform) aims to support scientists and innovators in their entrepreneurial journey by integrating them into a rich life sciences ecosystem. The VC firm emphasizes that it is built by a strong team and understands the capital-intensive nature and long gestation periods associated with R&D, helping bring innovative ideas to market.

Download the medial app to read full posts, comements and news.